Bernstein Liebhard LLP Investigating Risperdal Lawsuits on Behalf of Victims of Male Breast Growth Allegedly Caused by Risperdal
New York, New York (PRWEB) October 21, 2013 -- The nationwide law firm of Bernstein Liebhard LLP (http://www.consumerinjurylawyers.com) is investigating Risperdal lawsuits on behalf of young men and boys who developed a condition called gynecomastia, or male breast growth, allegedly due to their use of Risperdal.
“We are interested in hearing from anyone who developed gynecomastia or male breast growth while using Risperdal,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free Risperdal lawsuit consultations to any individual who may have developed gynecomastia due to Risperdal.
Risperdal and Male Breast Growth
According to its prescribing information, Risperdal is an atypical antipsychotic drug used to treat adult and adolescent schizophrenia, as well as bipolar disorder in adults and children ages 10-to-17. Risperdal is also approved to treat irritability in children (5-to-16 years of age) with autistic disorder.* Research also indicates that off- label use of Risperdal to treat ADHD is also on the rise.**
According to research published in 2006 in the Journal of Clinical Psychopharmacology, Risperdal may cause the body to produce excessive amounts of a hormone called prolactin, which is known to stimulate breast growth and milk production in women. Excessive levels of prolactin were associated with gynecomastia in boys and the development of lactation in girls, according to the study authors. ***
According to the Mayo Clinic, gynecomastia is the swelling of the breast tissue in boys or men. Symptoms of Gynecomastia may include:
• Swelling
• Pain
• Tenderness
• Nipple discharge in one or both breasts
In the most severe cases, liposuction or mastectomy may be required to treat gynecomastia.****
In October 2012, Bloomberg.com reported that Johnson & Johnson had agreed to settle five Risperdal lawsuits filed in Pennsylvania state court involving gynecomastia allegations.****
Individuals who were treated with Risperdal are urged to contact Bernstein Liebhard LLP for a free legal consultation if they developed gynecomastia or male breast growth while taking this drug. To learn more about filing a Risperdal lawsuit, please contact the Firm by calling 800-511-5092.
*accessdata.fda.gov/drugsatfda_docs/label/2009/020272s056,020588s044,021346s033,021444s03lbl.pdf, Risperdal Prescribing Information, FDA, 2009
**health.usnews.com/health-news/news/articles/2012/08/07/more-kids-taking-antipsychotics-for-adhd-study, U.S. News & World Report, August 7, 2012
***journals.lww.com/psychopharmacology/Abstract/2006/04000/Risperidone_induced_Symptomatic.10.aspx, Journal of Clinical Psychopharmacology, April 2006
****Bloomberg.com/news/2012-10-04/johnson-johnson-agrees-to-settle-five-rispersal-suits.html, Bloomberg.com, October 10, 2012
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 11 consecutive years.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092
ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com
http://www.consumerinjurylawyers.com
Felecia L. Stern, Bernstein Liebhard LLP, http://www.consumerinjurylawyers.com, +1 800-511-5092, [email protected]
Share this article